Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.
Thiem A, Schummer P, Ueberschaar S, Kerstan A, Kneitz H, Schrama D, Appenzeller S, Meierjohann S, Schilling B, Goebeler M, Gesierich A.
Thiem A, et al.
Melanoma Res. 2018 Oct;28(5):465-468. doi: 10.1097/CMR.0000000000000458.
Melanoma Res. 2018.
PMID: 29781871
After only one, respectively, two infusions of pembrolizumab, both patients developed melanuria and diffuse melanosis cutis (DMC) on sun-exposed areas of their skin. Both also had liver metastases, which have been reported to be associated with DMC before. ...We con …
After only one, respectively, two infusions of pembrolizumab, both patients developed melanuria and diffuse melanosis cutis (DMC) on sun …